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Abstract
Epidemiological methods for estimating disease prevalence in humans and other animals in the absence of a gold
standard diagnostic test are well established. Despite this, reporting apparent prevalence is still standard practice in
public health studies and disease control programmes, even though apparent prevalence may diﬀer greatly from the
true prevalence of disease. Methods for estimating true prevalence are summarized and reviewed. A computing
appendix is also provided which contains a brief guide in how to easily implement some of the methods presented
using freely available software.
Introduction
Accurate estimation of the prevalence of disease is an
essential part of both human and veterinary public health.
For many pathogens this estimation is complicated by
the lack of an appropriate reference test, that is, a diag-
nostic test which when applied to samples taken from a
given target population has known accuracy (e.g. a gold
standard/error free, or where the misclassiﬁcation error is
reliably known and understood). An important fact which
is often overlooked is that the accuracy of a diagnostic
test is a population speciﬁc parameter [1], as opposed to
some intrinsic constant, as it depends upon the speciﬁc
biological characteristics of the study population.
Despite the longstanding availability of approaches for
estimating disease prevalence in the presence of diagnos-
tic uncertainty, the use of such methods is still far from
common. For example, a recent review of 69 prevalence
studies [2] found that despite the lack of an available ref-
erence test, none of the studies provided either estimates
of true prevalence or indications as to the accuracy of the
diagnostics used.
When estimating disease status it is crucially important
to distinguish between analytical and diagnostic accuracy
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of a test. Analytical accuracy is concerned with repeata-
bility and robustness of the assay under laboratory con-
ditions, when applied to samples usually with a known
disease status [3]. In contrast, diagnostic accuracy is the
ability of the assay to correctly identify a truly diseased
subject from a non-diseased subject when applied to a
sample from a randomly chosen individual from a given
population of interest. This population may be deﬁned in
terms of biological characteristics, or else by geography or
any other relevant commonality. High analytical accuracy
does not imply high diagnostic accuracy. For example, a
diagnostic test may reasonably be considered a gold stan-
dard test when applied to one study population but not
another if these are epidemiologically diﬀerent (e.g. dif-
ferent levels of disease exposure to additional pathogens
or other biological confounders). Accuracy estimates pro-
vided by diagnostic test manufacturers should therefore
be treated with considerable caution.
Statistical models which can accommodate both sam-
pling error and misclassiﬁcation error when analyzing
data from imperfect diagnostic tests have been available in
the literature for many years [1,4-7]. Key methodological
articles include [8-13]. The development of more complex
variants and extensions is still an active ﬁeld of research
[14,15]. More recently, the use of Bayesian and hierarchi-
cal statistical modelling has become increasingly common
(e.g. [16-19]).
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To date it is rare to ﬁnd adjustment for diagnostic
accuracy in regression analyses, for example in risk fac-
tor studies. This is, however, arguably just as impor-
tant as in prevalence studies as when the diagnostic
used is not perfect then the estimated eﬀects of the
covariates identiﬁed will have standard errors which are
under-estimated (due to not incorporating the uncer-
tainty resulting from diagnostic error). Moreover, such
analyses identify those covariates related to apparent
rather than true prevalence. Analogous methods to those
reviewed here can also be used in regression analyses
(e.g. see [20]).
In some studies the key parameter of interest may be
disease prevalence, and estimates of the accuracy of the
diagnostic tests used are simply nuisance parameters.
Alternatively, it may be that the accuracy of the diag-
nostics themselves are of prime interest, for example if a
new test has been developed and it is desired to examine
whether it oﬀers improved accuracy against existing tests,
in which case disease prevalence is now a nuisance param-
eter. These two situations are mathematically identical,
and the objective is to identify an appropriate statistical
model which jointly estimates both disease prevalence and
diagnostic test accuracy in the absence of a gold standard
reference test.
We present here a brief overview of the key methods
and concepts necessary to estimate disease prevalence
and diagnostic test accuracy. While our focus is largely
on veterinary public health, the accuracy of diagnos-
tic tests used in veterinary medicine are highly variable,
these methods apply equally to diseases of humans. Our
objective is to provide an accessible, and non-technical
introduction, to facilitate more widespread use of these
techniques in analyses of data from epidemiological stud-
ies. We ﬁrst present some basic deﬁnitions followed by
thematic sections concerned with estimating disease sta-
tus: i) within a randomly sampled individual; ii) within
a single population group; and iii) across multiple pop-
ulation groups. We conclude with a brief discussion of
the limitations and caveats required when using these
techniques.
Preliminaries
Deﬁnitions
A number of technical terms and results are central
to analyses involving imperfect diagnostic tests and we
deﬁne some of these here. Sensitivity is deﬁned as the
probability that a diagnostic test is positive (T+) given
that the sample being tested is known with certainty to be
disease positive (D+). Similarly, speciﬁcity is the probabil-
ity that a diagnostic test is negative (T−) given that the
sample being tested is known with certainty to be disease
negative (D−). We denote sensitivity and speciﬁcity as Se
and Sp respectively. Given these deﬁnitions:
P(T+) = P(T+ | D+)P(D+) + P(T+ | D−)P(D−), (1)
P(T+) = Seπ + (1 − Sp)(1 − π) (2)
which relates the probability of observing a positive test
result, P(T+), to the true prevalence of disease in the study
population, π , and the sensitivity and speciﬁcity of the
test. Two other important results are
PPV : P(D+ | T+) = SeπSeπ + (1 − Sp)(1 − π) , (3)
NPV : P(D− | T−) = Sp(1 − π)
(1 − Se)π + Sp(1 − π) (4)
where P(D+ | T+) denotes the positive predictive value,
PPV, of the test, that is the probability that if the test is
positive then the sample is truly disease positive. Similarly
P(D− | T−) is the negative predictive value, NPV. These
results can be found in any standard epidemiology text
(e.g. [21]).
The most commonly used probability model to describe
sampling error when estimating disease prevalence is the
binomial distribution. With r test positive subjects out of
n tested, and p denoting the probability of observing a test
positive subject then:
P(observe r test positive out of n | p) =
(n
r
)
pr(1− p)n−r ,
(5)
and combining this with equation (2) gives
P(observe r test positive out of n | p) =(n
r
)(
Seπ+(1−Sp)(1−π)
)r(1−Seπ−(1−Sp)(1−π))n−r .
(6)
The statistical model in equation (6) is arguably the sim-
plest model for estimating disease prevalence and diag-
nostic error, although note that it is over-parameterized
with three parameters (π , Se, Sp) but only one piece of
information provided by the data (the apparent preva-
lence, r/n). As such, this model is only of practical use
within a Bayesian context (see later) as this allows for addi-
tional (prior) information about π , Se and Sp to be used to
supplement the observed data. Related to equation (6) is
the classic Rogan-Gladen estimator of true prevalence in
the presence of an imperfect diagnostic test [22]. This esti-
mator has the advantage of simplicity but it requires that
Se and Sp are both known (and constant), which may be
unrealistic in practice. In addition, the Rogan-Gladen esti-
mator can produce estimates of prevalence which exceed
one or are negative [23], (in which case the values of Se and
Sp must be incorrect for the current population of inter-
est). Generally speaking, other more modern approaches
such as those subsequently presented are preferable.
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Fitting models to data
Consider the simple model given in equation (6), and sup-
pose we have observed data which comprises of n = 50
subjects tested, using some imperfect diagnostic, and of
these r = 15 are test positive. We wish to use this infor-
mation to estimate the true prevalence of disease in the
population from which these n = 50 subjects were sam-
pled. In general, ﬁtting such a model to data typically
requires writing (a few lines of ) bespoke computer code
in specialist software, e.g. WinBUGS/OpenBUGS [24] or
JAGS [25], as opposed to relying on built-in functionality
as would be the case with, for example, logistic regression
modelling.
One of three broad numerical techniques is typically
utilized. The classic approach is a direct application of
maximum likelihood estimation [8]. An alternative is to
use the Expectation Maximization (EM) algorithm [26],
which is also a maximum likelihood approach but ide-
ally suited to problems comprising latent class variables,
which is exactly what we have here as the true disease sta-
tus of each observation is only latently observed. Some
details of how to implement EM estimation in the context
of imperfect diagnostic tests are given in [27] and [20].
The third option is to use a Bayesian approach. There is
a vast literature on Bayesian statistics, two widely used
standard texts are [28] and [29]. A brief non-technical
veterinary focused introduction to these three techniques
can be found in [4].
A key distinction between Bayesian and maximum like-
lihood modelling is that in a Bayesian approach prior
knowledge about likely values for the parameters in the
statistical model must be included. There are two options
here: i) non-informative priors, which in eﬀect, do not
incorporate any prior knowledge about the parameters of
interest into the modelling process; and ii) “data-driven”
priors in the sense that some evidence — external to
the current study data — for example, expert opinion
from appropriate specialists or existing relevant litera-
ture, is available about likely values for one or more of
the parameters of interest. Note also that non-informative
(e.g. vague) priors need not be on the range [ 0, 1], for
example, a Gaussian distribution with zeromean and large
variance (e.g. 1000) may be appropriate when parameter-
izing prevalence or test accuracies in terms of covariates
(e.g. the ﬁnal example in the computing appendix). If a
data-driven prior is chosen then it is absolutely essential
that such a choice can be robustly justiﬁed, i.e. it is not
some arbitrary guess, as this may have a strong inﬂuence
on the modelling results obtained.
Considering the model in equation (6), in a Bayesian
context we would need to additionally provide informa-
tion/prior assumptions about likely values for the true
prevalence in the population of interest, along with esti-
mates of the test’s sensitivity and speciﬁcity. In practice
the ability to include prior knowledge can be highly bene-
ﬁcial as it is common to be able to say at least something,
even if this is very vague - provided it is justiﬁable -
about the likely value of the true prevalence of a disease
(e.g. < 80%) or the likely range of sensitivity and speci-
ﬁcity for a given diagnostic. This prior information can
be as strong or weak as required including, in eﬀect, no
prior knowledge where it is simply assumed that π , Se
and Sp lie between zero and one and can be any value in
between with equal probability. Generally speaking, the
results from a Bayesian analysis which uses little or no
prior knowledge often give results which are extremely
similar to those from maximum likelihood.
Other than the obvious attraction of being able to incor-
porate prior information into any analyses, a Bayesian
approach also has an important practical advantage: sev-
eral high quality software packages (JAGS and Open-
BUGS) are available which can be used with relative ease
to ﬁt Bayesian models appropriate for estimating true dis-
ease prevalence and imperfect diagnostic accuracy. Some
bespoke computer code is still required, although this
comprises mainly of deﬁning the desired model in a way
which can be understood by JAGS/OpenBUGS. While
such models may be easy to ﬁt to data, in common with
all Bayesian modelling careful diagnostic and sensitivity
analyses are essential [28].
The computing appendix (see Additional ﬁle 1) con-
tains a detailed guide in how to write code for ﬁtting
and comparing models for estimating disease prevalence
and diagnostic accuracy in JAGS. Starting with the simple
example given in equation (6), it is shown how this code
can be readily extended to incorporate highly complex
models. Also provided is how to choose between com-
peting models using the Deviance Information Criterion
(DIC) [30] - as model selection in any statistical analy-
sis is crucial for ensuring robust results. While the DIC is
very commonly used in Bayesian analyses, and is straight-
forward to estimate, it is not without its critics and its
reliability in some situations is an active area of statisti-
cal research (e.g. [31]) . The code required by OpenBUGS
and JAGS is broadly similar, but a considerable attraction
of JAGS is its very simple command line interface and that
it is available for many diﬀerent platforms (e.g. windows,
mac and linux). For R [32] users the rjags library provides a
way to run analyses in JAGS without leaving R, and works
across all platforms, although this does still ﬁrst require
familiarity with the JAGS user manual.
Statistical models for use with imperfect diagnostic
tests
Disease presence within an individual subject
If the diagnostic test used is not a gold standard, then on
observing a positive test result for a given subject, the key
question is how likely is it that this subject is truly disease
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positive? This is the PPV (equation 3) and its value may
depend on many things, not least the true prevalence of
disease within the population from which the particular
subject has its provenance.
To show the considerable public health ramiﬁcations
that failing to account for imperfect diagnostic accuracy
can have, we present a very simple but real epidemi-
ological example based on a recent legal case in the
UK [33]. Consider a farm with 118 cattle undergoing rou-
tine surveillance for bovine tuberculosis (bTB) using the
comparative intra-dermal skin test in the north east of
England where bTB is rarely seen. One animal has a pos-
itive test result. The skin test has a sensitivity of ≈ 0.78
and speciﬁcity of ≈ 0.999 [34]. With an apparent preva-
lence of 1/118 the true herd prevalence π using equation
(1) can be estimated at ≈ 0.0096. There is available a sec-
ondary blood test for bTB based on an interferon gamma
assay (IFNg). Because of the ongoing epidemic of bTB in
the UK, DEFRA (Department for Environment, Food and
Rural Aﬀairs) has a policy of testing all animals with IFNg
on a farm where bTB is conﬁrmed providing the farm is
in an area of the UK where bovine bTB does not usually
occur [35]. Should one of the remaining 117 animals on
the farm be positive to this secondary test a question that
could be asked is what is the probability the animal has
tuberculosis (i.e. the PPV of the secondary test)? The sen-
sitivity and speciﬁcity of the interferon gamma test are
reported as 0.909 and 0.965 respectively [36]. Therefore,
in this case we have π = 0.0096, Se = 0.909, Sp = 0.965
and hence a PPV of 0.201. Therefore, the probability of a
false positive is 0.799. This may be one reason why many
cattle giving a positive INFg test result, originating from
such low endemic districts, have no evidence of infection
at post mortem [35]. This simple example demonstrates
the dangers of incorrectly treating an imperfect diagnos-
tic test as error free, or equivalently interpreting apparent
prevalence as true prevalence.
Assessing the disease status of any individual subject
is, to a greater or lesser extent, probabilistic in nature.
As the above example highlights, however, when dealing
with imperfect tests and diseases with low prevalence then
the chance of observing a false positive result even with
extremely speciﬁc diagnostic tests can be appreciable. It is
therefore essential to always estimate the PPV.
Disease prevalence within populations of subjects
One of the most well cited and founding articles in anal-
yses of data from imperfect diagnostic tests is by Hui
and Walter [8] who are credited with deriving rules for
study designs which allow for the sensitivity and speci-
ﬁcity of imperfect diagnostic tests, and the associated true
prevalence of disease, to be estimated.
In short, using multiple imperfect diagnostic tests and
one or more independent populations of animals, with
diﬀering prevalences, provides suﬃcient information to
allow all model parameters to be estimated. Consider two
examples: i) one population of 100 subjects are tested
for disease, and each individual is tested using three dif-
ferent diagnostic tests (of uncertain accuracy), and it is
assumed that the tests provide (biologically) indepen-
dent results. This study design provides seven degrees of
freedom (seven independent pieces of information), the
counts of how many subjects out of 100 have each test
pattern, e.g. suppose 15 individuals have (T+1 ,T
+
2 ,T
−
3 ) —
positive results for test 1 and test 2 but negative for test
3. There are eight possible patterns but since the total
number of subjects is ﬁxed then there are only seven inde-
pendent counts. This study design has seven parameters
which need to be estimated: π , Se1 , Sp1 , Se2 , Sp2 , Se3 , Sp3
— the true prevalence plus the sensitivity and speciﬁcity
of each test. Hence, we have seven parameters and seven
degrees of freedom and therefore each parameter can be
estimated as, generally speaking, it requires one degree of
freedom to estimate each parameter in a model.
For a second example consider two independent popu-
lations (with assumed diﬀerent prevalences), where each
subject is tested using two imperfect (and assumed inde-
pendent) tests. This time we have six parameters to esti-
mate π1, π2, Se1 , Sp1 , Se2 , Sp2 , the prevalence in each pop-
ulation and the sensitivity and speciﬁcity of each test. In
each population we have three degrees of freedom - three
independent counts, one for each test pattern, (T+1 ,T
−
2 )
etc, so again can estimate all the parameters required.
In summary, by adding additional population groups
and/or additional tests then the unknown diagnostic sen-
sitivity and speciﬁcity, and true disease prevalence, can be
estimated. A number of important caveats apply to these
study designs. In particular, it may be unreasonable to
assume that the diagnostic tests used will be independent
as they may share a similar biological basis.
The Hui and Walter “rules” apply only to maximum
likelihood estimation of the model parameters, tech-
nically speaking these criteria ensure the model is
identiﬁable, that each parameter in the model can be
uniquely estimated given only the observed data. See [37]
for a detailed examination of identiﬁability in respect of
models for imperfect diagnostic tests. It should also be
noted that the Hui andWalter approach can perform very
poorly in situations where the prevalences across diﬀer-
ent populations are similar [38]. When using a Bayesian
approach the situation is more ﬂexible as the use of prior
information can allow all model parameters to be readily
estimated [11]. For example, the model in equation (6)
does not meet the Hui and Walter rules as it has only one
test and one population, and with three parameters these
cannot be estimated uniquely using maximum likelihood
— but can be readily estimated in a Bayesian context pro-
vided suﬃcient prior information is available (subject to
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some technical caveats such as the use of a proper prior,
see [28]).
Correlated Diagnostic Tests
In Hui and Walter is it assumed that the diagnostic tests
being used were conditionally independent, e.g. given a
known positive sample then
P(T+1 ,T
+
2 | D+) = P(T+1 | D+)P(T+2 | D+)
= Se1Se2 . (7)
This is only tenable, however, if the tests are based on
diﬀerent biology, for example gross pathology and PCR,
otherwise is it diﬃcult to justify that each test provides
independent evidence in support of the presence (or oth-
erwise) of disease. Developing models which can incor-
porate dependence between test results comprises a large
body of work, with one of the ﬁrst examples being [9]
followed by many others (e.g. [12,13,39,40]). The impact
of assuming conditional independence between tests, or
indeed assuming a particular dependency structure, is
of crucial importance in such analyses [6,27,41] and we
return to this later. There are a number of diﬀerent ways
to incorporate adjustment for correlation between tests,
following [13] the basic idea is as follows:
P(T+1 ,T
+
2 | D+) = P(T+1 | D+)P(T+2 | D+)
= Se1Se2 + covs, (8)
where compared to equation (7) an additional parame-
ter is introduced whose purpose is simply to provide a
numerical adjustment to ensure that the conditional prob-
ability P(T+1 ,T
+
2 | D+) is no longer equal to the product
of the test sensitivities. The statistical price for introduc-
ing covariance terms (e.g. covs) is that each one of these
requires a degree of freedom in the study design and so
additional populations and/or tests are required. How best
to utilize the degrees of freedom available in any given
study design is crucial in selecting an appropriate statis-
tical model. Degrees of freedom can be “saved” by ﬁxing
or collapsing parameters in the model, for example by
assuming that one or more of the tests are 100% speciﬁc or
that two tests may have approximately the same speciﬁcity
but diﬀerent sensitivities.
We now present a brief empirical example comprising of
multiple (three) imperfect and potentially correlated tests.
All the JAGS (and R) code, and the data necessary to con-
duct this example, along with detailed instructions, can be
found in the computing appendix (together with several
other related examples). Consider the situation where we
have one population of 200 subjects, and where each is
tested once with three diﬀerent diagnostic tests. We ﬁnd
that the (mean) apparent prevalence is 44% (88/200) and
we wish to estimate the true prevalence. In terms of prior
knowledge based on known biology and expert experience
of the assays involved, we assume that the speciﬁcity for
the third test is perfect (100%), and use prior Beta distri-
butions for the speciﬁcity of the ﬁrst and second tests of
Be(9, 1) for each, e.g. amean of 90% accuracy and 2.5% and
97.5% quantiles of approximately 66.4% and 99.7% respec-
tively. Non-informative, e.g. Be(1, 1), priors are used for
all other parameters. In other words, we are fairly conﬁ-
dent that the speciﬁcity of the ﬁrst and second tests will
be reasonably good but we are not sure of exactly how
good. We have no other evidence to assert prior knowl-
edge into themodelling in respect of the other parameters.
We also cannot discount (on biological grounds) covari-
ance between the tests, and explicitly include a term in our
model for covariance between the second and third tests
when the subject truly has disease. Given the data, our
prior assumptions (distributions) and our model struc-
ture, i.e. amultinomial model parameterised as three tests,
one population and one covariance term, we can then use
JAGS to produce an estimate of the true prevalence. We
ﬁnd using this particular model formulation that themean
true prevalence is 36.2% (see the computing appendix
for detailed parameter estimates). What is also of some
note is that if we were to assume that all these tests were
conditionally independent (i.e. no covariance terms) then
our mean estimate of the true prevalence drops to 18.3%
(this example is also in the computing appendix). This
highlights the crucial importance of model selection (as
discussed later), and that it is essential to consider diﬀer-
ent covariance structures between tests, and then choose
that which is most supported by the observed data.
Disease prevalence across multiple population groups
In disease surveillance the objective is typically wider than
estimating disease prevalence or diagnostic accuracy in
respect of one or more independent population groups,
but where estimates are desired across a large number of
groups. This is particularly true when considering popu-
lations of food animals, where a main question of interest
is the prevalence of disease in the national herd rather
than on an individual farm. If multiple test results were
available per subject/animal - which is uncommon due
to the very considerable resources required - then such
studies could be analyzed using the one population mul-
tiple test design (e.g. [27]). When considering populations
structured into groups (i.e. farms or herds in the case of
livestock), then issues such as within group correlation
eﬀects may need to be taken into account. In particular,
what is typically desired is an estimate of the distribu-
tion of within-group (e.g. herd) disease prevalences based
on observations from some random subset of individual
groups.
In [19] a veterinary case study is presented utilizing a
hierarchical model involving multiple herds and two con-
ditionally independent tests, where the goal is to estimate
the distribution of within-herd prevalences across many
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herds. A discussion of herd level testing in the absence
of a gold standard diagnostic can also be found in [7].
A particularly important design of study is where only a
single imperfect diagnostic test is used across many pop-
ulation groups, and such studies are amenable to analyzes
which can be done in various ways. Using a hierarchical
modelling approach such as the beta-binomial technique
presented in [7] or alternatively using ﬁnite mixture mod-
elling which seeks to identify distinct prevalence cohorts
within a population [42]. While these are mathematically
rather sophisticated models they are little more diﬃcult to
code in JAGS than other simpler models. Other ways to
estimate the distribution of true prevalence across many
population groups when only a single imperfect diagnos-
tic test is available is to exploit laboratory replicates, as
this can greatly increase the amount of data available in
a study, but some care is required as replicates from the
same subject will likely be correlated [43].
Reliability and Validation
While methodological contributions and case studies esti-
mating disease prevalence and the accuracy of diagnostic
tests represents a sizable body of work, there are outstand-
ing technical and conceptual issues. In particular, as the
true prevalence is not directly observed but only latently
observed (unlike apparent prevalence) such models are
not testable against observed data without other addi-
tional information [27]. Many statistical models, however,
comprise of latent parameters, which are a necessary part
of their formulation. One very common example being
linear mixed models [44], and methods for estimating
such parameters are well established.
As with all statistical modelling, the resulting parameter
estimates will only approximate nature’s true values (as the
complete biological and physical mechanisms which gen-
erated the observed data will generally be unknown), and
the estimates of these values will depend on the precise
formulation of the chosen statistical model. It is, therefore,
absolutely crucial to select the most appropriate model for
given study data by comparing - possibly numerous - dif-
ferent competing models. This is particularly true when
estimating such unobservable (latent) parameters as true
disease prevalence and diagnostic accuracy. Assessing the
impact of diﬀerent assumptions in regard to dependence
between tests or assumptions relating to the prevalence
distribution across population groups, e.g. is a disease
free cohort needed if many individual groups are free
from disease, can be of considerable practical importance
[19,27,42,43,45].
While prevalence estimation and diagnostic accuracy
are strongly biologically driven it is still essential to per-
form robust model selection. The choice of sampling
distribution is arguably less of an issue here than in other
types of analyses, as generally speaking we typically have
sets of dependent Bernoulli trials (although some studies
do require additional measures such as zero inﬂation or
over-dispersion for within group clustering). The model
selection process here typically centres around choosing
the optimal covariance structure between diﬀerent diag-
nostic tests. For example, if there are three or four (or
more) tests then there are a great many diﬀerent covari-
ance structures possible. Ideally we wish to determine that
which is most optimal given the observed data.While bio-
logical knowledge can obviously be helpful here, this is, in
practice, something of a challenge. A diagnostic test which
is based on a serological assay may be reasonably con-
sidered (conditionally) independent from a diagnostic test
which uses gross pathology, and so the relevant covari-
ance parameters set to zero. This is, however, much more
diﬃcult to argue when diﬀerent serological based tests
are used together, or other tests which are based on simi-
lar biological mechanisms. It may be assumed apriori that
such tests may be covariant (dependent), but that is rather
diﬀerent from whether the observed study data actually
supports such an assertion. In order to determine an opti-
mal (parsimonious) model then extensive model selection
comparing the goodness of ﬁt (e.g. DIC) across diﬀerent
covariance structures is essential. Not only because this
is of interest in terms of the biological results, but also
because this may have a substantive impact on the result-
ing estimates of the parameters of interest, e.g. prevalence
and diagnostic accuracies.
There are very few simulation/validation studies in the
literature, e.g. where the results of a model are com-
pared with the “truth”. One example can be found in [27]
who compare results from a model of a single sample of
666 observations and three imperfect tests, with results
from a known gold standard test. The model used in this
example under-estimates the true prevalence of disease
(42% against 54%) and over-estimates the accuracy of the
diagnostic tests. Another example, which uses diﬀerent
animals for the imperfect and gold standard comparison,
can be found in [46].
A potential diﬃculty in assessing model robustness
using simulation is that the parameters estimated may
be all highly interdependent, and therefore how well any
model performs may depend closely on the precise com-
bination of (true) values used. This is particularly prob-
lematic when considering the general case of estimating
prevalence across a group of populations, e.g. farms, as
there are the additional parameters required to describe
the shape of the within-herd prevalence distribution, and
this may take almost any shape. Using simulation stud-
ies to draw general conclusions as to the likely situations
in which some models may perform better than others is
therefore a signiﬁcant challenge, and may partly explain
the lack of such studies in the literature.
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Finally, before conducting any analyses it is essential to
clearly deﬁne the disease status being examined, e.g. what
constitutes a sample being disease positive, as without
this, while the models can still be ﬁtted and parameters
estimated, the numerical results will have no meaningful
biological interpretation.
Conclusion
There is a broad and established literature on estimat-
ing the prevalence of disease in humans and animals in
the absence of a gold standard diagnostic test. There is,
therefore, little scientiﬁc justiﬁcation for reporting appar-
ent prevalence in place of true prevalence, and similarly
assuming diagnostic tests are either gold standard tests or
have known accuracy when this has not been established
on the particular study population. The main practical
obstacle in applying such techniques is that the analyses
required are not pre-built into standard statistical soft-
ware, however, using more specialist programs such as
JAGS/OpenBUGS appropriate analyses can be conducted
with relative ease.
Additional ﬁle
Additional ﬁle 1: Computing Appendix Bundle. This comprises of
collection of text ﬁles plus a pdf document which contains a simple
“HOWTO” guide for estimating disease prevalence in the absence of a gold
standard diagnostic. These are simple examples using Bayesian statistical
modelling via Markov chain Monte Carlo simulation via the open source
JAGS software. The syntax used by JAGS is broadly similar to OpenBUGS
and it is relatively easy to switch between the two. An attractive feature of
JAGS is its very simple command line.
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